Abstract
MicroRNA-183 (miR-183) has recently been identified to be implicated in a variety of critical processes in multiple human malignancies, and its fuction has been poorly characterized in gastric cancer (GC). Here we reported that miR-183 was markedly over-expressed in GC and its up-regulation was markedly associated with GC clinicopathologicalcharacters. Endogenous miR-183 was inhibited in GC cells, which dramatically attenuated cell proliferation, colony formation, migration, invasion and adhesion and enhancedGC cells apoptosis in vitro. Furthermore, in this study we demonstrated that the tumor suppressor gene PDCD4 was a target of miR-183 in GC. Collectively, these observations showed that miR-183 maybe function as an oncogene by regulating GC cell proliferation, apoptosis and metastasis and the oncogenic effect of miR-183 may relate the direct targeting PDCD4.
Keywords: Apoptosis, gastric cancer, metastasis, MicroRNA-183, PDCD4, proliferation.
Anti-Cancer Agents in Medicinal Chemistry
Title:MicroRNA-183 Functions As an Oncogene by Regulating PDCD4 in Gastric Cancer
Volume: 16 Issue: 4
Author(s): Chenglong Li, Li Deng, Qiaoming Zhi, Qingyou Meng, Aimin Qian, Hongfei Sang, Xiaoqiang Li and Jiazeng Xia
Affiliation:
Keywords: Apoptosis, gastric cancer, metastasis, MicroRNA-183, PDCD4, proliferation.
Abstract: MicroRNA-183 (miR-183) has recently been identified to be implicated in a variety of critical processes in multiple human malignancies, and its fuction has been poorly characterized in gastric cancer (GC). Here we reported that miR-183 was markedly over-expressed in GC and its up-regulation was markedly associated with GC clinicopathologicalcharacters. Endogenous miR-183 was inhibited in GC cells, which dramatically attenuated cell proliferation, colony formation, migration, invasion and adhesion and enhancedGC cells apoptosis in vitro. Furthermore, in this study we demonstrated that the tumor suppressor gene PDCD4 was a target of miR-183 in GC. Collectively, these observations showed that miR-183 maybe function as an oncogene by regulating GC cell proliferation, apoptosis and metastasis and the oncogenic effect of miR-183 may relate the direct targeting PDCD4.
Export Options
About this article
Cite this article as:
Li Chenglong, Deng Li, Zhi Qiaoming, Meng Qingyou, Qian Aimin, Sang Hongfei, Li Xiaoqiang and Xia Jiazeng, MicroRNA-183 Functions As an Oncogene by Regulating PDCD4 in Gastric Cancer, Anti-Cancer Agents in Medicinal Chemistry 2016; 16 (4) . https://dx.doi.org/10.2174/1871520615666150914114237
DOI https://dx.doi.org/10.2174/1871520615666150914114237 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patent Selections
Recent Patents on Biomarkers Natural Monoclonal Antibodies and Cancer
Recent Patents on Anti-Cancer Drug Discovery 18F-FAZA PET/CT in the Preoperative Evaluation of NSCLC: Comparison with 18F-FDG and Immunohistochemistry
Current Radiopharmaceuticals Potential Prognostic Predictors and Molecular Targets for Skin Melanoma Screened by Weighted Gene Co-expression Network Analysis
Current Gene Therapy Visfatin: Structure, Function and Relation to Diabetes Mellitus and Other Dysfunctions
Current Medicinal Chemistry Molecule of the Month
Current Topics in Medicinal Chemistry CD147/EMMPRIN and CD44 are Potential Therapeutic Targets for Metastatic Prostate Cancer
Current Cancer Drug Targets Development of Radiotracers for the Determination of the Beta-Cell Mass In Vivo
Current Pharmaceutical Design The Pivotal Role of Nitric Oxide: Effects on the Nervous and Immune Systems
Current Pharmaceutical Design Current Progress of Lipid Analysis in Metabolic Diseases by Mass Spectrometry Methods
Current Medicinal Chemistry Pharmacotherapy in Systemic Lupus Erythematosus
Current Rheumatology Reviews Role of Hydrogen Sulfide and Polysulfides in Neurological Diseases: Focus on Protein S-Persulfidation
Current Neuropharmacology Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer
Mini-Reviews in Medicinal Chemistry Harmine Induces Gastric Cancer Cell Apoptosis through the ROSmediated PI3K/AKT Signaling Pathway
Current Signal Transduction Therapy Modulation of the Cell Cycle and Induction of Apoptosis in Human Cancer Cells by Synthetic Bile Acids
Current Cancer Drug Targets Formulation and Stability Aspects of Nanosized Solid Drug Delivery Systems
Current Pharmaceutical Design The Importance of Guidelines in the Development and Application of Probiotics
Current Pharmaceutical Design Pharmacological Activity of Natural Non-glycosylated Triterpenes
Mini-Reviews in Organic Chemistry MicroRNA and Bone Tumor: To Up Date
Current Signal Transduction Therapy Ganoderma lucidum (Ling-zhi): The Impact of Chemistry on Biological Activity in Cancer
Current Bioactive Compounds